Use Of Oral Janus Kinase Inhibitors For The Treatment Of Severe Alopecia Areata: Narrative Review And Real-World Experience

    March 2026 in “ Immunological Medicine ”
    Manabu Ohyama, M. Fukuyama, Reina Hayakawa, Misaki Kinoshita-Ise
    Studysummary This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on tandfonline.com →
    Discuss this study in the Community →

    Research cited in this study 31

    1. Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib Journal of Clinical Medicine · 2025
    2. Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata Dermatology and Therapy · 2025
    3. Safety of Oral JAK Inhibitors in Treating Alopecia Areata: A Systematic Review and Network Meta-Analysis Frontiers in Pharmacology · 2025
    4. Long-Term Real-World Outcomes of Baricitinib in Severe Alopecia Areata: A 104-Week Retrospective Analysis From a Single Institute The Journal of Dermatology · 2025
    5. Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment American Journal of Clinical Dermatology · 2025
    6. Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib PubMed · 2025
    7. Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme Journal of the European Academy of Dermatology and Venereology · 2025
    8. Predictive Factors for Treatment Responses to Baricitinib in Severe Alopecia Areata: A Retrospective, Multivariate Analysis of 70 Cases from a Single Center The Journal of Dermatology · 2025
    9. Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study Journal of the European Academy of Dermatology and Venereology · 2025
    10. Real-Life Effectiveness and Safety of Baricitinib in 17 Japanese Patients With Alopecia Areata: A 60-Week Single Center Study Journal of Cutaneous Immunology and Allergy · 2025
    11. Continued Treatment With Baricitinib Results in Meaningful Scalp Responses Among Scalp Non-Responder Patients With Eyebrow/Eyelash Regrowth in the First Year Journal of the European Academy of Dermatology and Venereology · 2024
    12. Systematic Review and Indirect Treatment Comparisons of Ritlecitinib Against Baricitinib in Alopecia Areata Journal of the European Academy of Dermatology and Venereology · 2024
    13. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata JAMA Dermatology · 2024
    14. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    15. Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients Acta dermato-venereologica · 2024
    16. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
    17. Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials British Journal of Dermatology · 2023
    18. Economic Burden of Alopecia Areata: A Study of Direct and Indirect Cost in Japan Using Real-World Data Journal of dermatology · 2023
    19. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    20. Prevalence of Alopecia Areata in Japan: Estimates from a Nationally Representative Sample The Journal of Dermatology · 2022
    21. Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial Journal of the American Academy of Dermatology · 2021
    22. Two Cases in Which Tofacitinib Effectively Treated Both Ulcerative Colitis and Alopecia Areata Clinical Journal of Gastroenterology · 2020
    23. What Is Behind the 'Swarm of Bees' in Alopecia Areata British Journal of Dermatology · 2018
    24. Comorbidities in Alopecia Areata: A Systematic Review and Meta-Analysis Journal of The American Academy of Dermatology · 2018
    25. Alopecia Areata: A Review of Disease Pathogenesis British journal of dermatology/British journal of dermatology, Supplement · 2018
    26. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    27. British Association of Dermatologists’ Guidelines for the Management of Alopecia Areata 2012 British Journal of Dermatology · 2012
    28. Alopecia Areata: An Autoimmune Disease Causing Hair Loss The New England Journal of Medicine · 2012
    29. Prevalence of Dermatological Disorders in Japan: A Nationwide, Cross-Sectional, Seasonal, Multicenter, Hospital-Based Study Journal of Dermatology · 2011
    30. Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack Journal of Investigative Dermatology · 2007
    31. Androgen-Inducible TGF-β1 from Balding Dermal Papilla Cells Inhibits Epithelial Cell Growth: A Clue to Understanding Paradoxical Effects of Androgen on Human Hair Growth ˜The œFASEB journal · 2002